CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 89 enrolled
Drug / intervention
prazosin hydrochloride +1 moredrug
Likely dose
prazosin hydrochloride 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02266329
NCT02266329Phase 2Completed
CompareCT.gov

Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin

VA Office of Research and Development·interventional·Posted Oct 17, 2014·Updated Mar 30, 2026

In Brief

A Phase 2 clinical trial evaluating prazosin hydrochloride and placebo for Posttraumatic Headache and 5 related conditions. Completed, enrolled 89 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if prazosin is more effective than placebo in decreasing frequency, severity, disability, and other negative effects of headaches related to mild traumatic brain injury in Service Members and Veterans.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPosttraumatic Headache, Combat Disorders, Post Concussion Syndrome, Headache, Mild Traumatic Brain Injury, Posttraumatic Migraine
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 17, 2014
Enrollment StartJan 4, 2016
Primary CompletionMay 31, 2023
Study CompletionSep 30, 2023
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 11.7 years ago

Interventions

prazosin hydrochloridedrug

Prazosin as oral capsules titrated to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.

placebodrug

Oral capsules of placebo identical in appearance to prazosin capsules titrated in the same manner as prazosin.